Your browser doesn't support javascript.
loading
Complement activation induces excessive T cell cytotoxicity in severe COVID-19.
Georg, Philipp; Astaburuaga-García, Rosario; Bonaguro, Lorenzo; Brumhard, Sophia; Michalick, Laura; Lippert, Lena J; Kostevc, Tomislav; Gäbel, Christiane; Schneider, Maria; Streitz, Mathias; Demichev, Vadim; Gemünd, Ioanna; Barone, Matthias; Tober-Lau, Pinkus; Helbig, Elisa T; Hillus, David; Petrov, Lev; Stein, Julia; Dey, Hannah-Philine; Paclik, Daniela; Iwert, Christina; Mülleder, Michael; Aulakh, Simran Kaur; Djudjaj, Sonja; Bülow, Roman D; Mei, Henrik E; Schulz, Axel R; Thiel, Andreas; Hippenstiel, Stefan; Saliba, Antoine-Emmanuel; Eils, Roland; Lehmann, Irina; Mall, Marcus A; Stricker, Sebastian; Röhmel, Jobst; Corman, Victor M; Beule, Dieter; Wyler, Emanuel; Landthaler, Markus; Obermayer, Benedikt; von Stillfried, Saskia; Boor, Peter; Demir, Münevver; Wesselmann, Hans; Suttorp, Norbert; Uhrig, Alexander; Müller-Redetzky, Holger; Nattermann, Jacob; Kuebler, Wolfgang M; Meisel, Christian.
Afiliación
  • Georg P; Department of Infectious Diseases and Respiratory Medicine, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin, Germany.
  • Astaburuaga-García R; Institute of Pathology, Charité - Universitätsmedizin Berlin, Berlin, Germany; IRI Life Sciences, Humboldt-Universität zu Berlin, Berlin, Germany.
  • Bonaguro L; Genomics and Immunoregulation, Life and Medical Sciences (LIMES) Institute, University of Bonn, Bonn, Germany; Systems Medicine, Deutsches Zentrum für Neurodegenerativen Erkrankungen (DZNE), Bonn, Germany.
  • Brumhard S; Department of Infectious Diseases and Respiratory Medicine, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin, Germany.
  • Michalick L; Institute of Physiology, Charité - Universitätsmedizin Berlin, Berlin, Germany.
  • Lippert LJ; Department of Infectious Diseases and Respiratory Medicine, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin, Germany.
  • Kostevc T; Institute of Medical Immunology, Charité - Universitätsmedizin Berlin, Berlin, Germany.
  • Gäbel C; Institute of Medical Immunology, Charité - Universitätsmedizin Berlin, Berlin, Germany.
  • Schneider M; Institute of Medical Immunology, Charité - Universitätsmedizin Berlin, Berlin, Germany.
  • Streitz M; Institute of Medical Immunology, Charité - Universitätsmedizin Berlin, Berlin, Germany.
  • Demichev V; Molecular Biology of Metabolism Laboratory, The Francis Crick Institute, London, UK; Department of Biochemistry, Charité - Universitätsmedizin Berlin, Berlin, Germany; Department of Biochemistry, Cambridge Centre for Proteomics, University of Cambridge, Cambridge, UK.
  • Gemünd I; Genomics and Immunoregulation, Life and Medical Sciences (LIMES) Institute, University of Bonn, Bonn, Germany; PRECISE Platform for Genomics and Epigenomics at DZNE, University of Bonn, Bonn, Germany; Department of Microbiology and Immunology, The University of Melbourne at the Peter Doherty Institu
  • Barone M; Institute of Medical Immunology, Charité - Universitätsmedizin Berlin, Berlin, Germany.
  • Tober-Lau P; Department of Infectious Diseases and Respiratory Medicine, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin, Germany.
  • Helbig ET; Department of Infectious Diseases and Respiratory Medicine, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin, Germany.
  • Hillus D; Department of Infectious Diseases and Respiratory Medicine, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin, Germany.
  • Petrov L; Institute of Medical Immunology, Charité - Universitätsmedizin Berlin, Berlin, Germany.
  • Stein J; Institute of Medical Immunology, Charité - Universitätsmedizin Berlin, Berlin, Germany.
  • Dey HP; Institute of Medical Immunology, Charité - Universitätsmedizin Berlin, Berlin, Germany.
  • Paclik D; Institute of Medical Immunology, Charité - Universitätsmedizin Berlin, Berlin, Germany.
  • Iwert C; Institute of Medical Immunology, Charité - Universitätsmedizin Berlin, Berlin, Germany.
  • Mülleder M; Core Facility, High Throughput Mass Spectrometry, Charité - Universitätsmedizin Berlin, Berlin, Germany.
  • Aulakh SK; Molecular Biology of Metabolism Laboratory, The Francis Crick Institute, London, UK.
  • Djudjaj S; Institute of Pathology, University Clinic Aachen, RWTH Aachen, Aachen, Germany.
  • Bülow RD; Institute of Pathology, University Clinic Aachen, RWTH Aachen, Aachen, Germany.
  • Mei HE; Mass Cytometry Laboratory, DRFZ Berlin, A Leibniz Institute, Berlin, Germany.
  • Schulz AR; Mass Cytometry Laboratory, DRFZ Berlin, A Leibniz Institute, Berlin, Germany.
  • Thiel A; Si-M/"Der Simulierte Mensch" a Science Framework of Technische Universität Berlin and Charité - Universitätsmedizin Berlin, Berlin, Germany; Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt - Universität zu Berlin, and Berlin Institute of Health, Berlin, G
  • Hippenstiel S; Department of Infectious Diseases and Respiratory Medicine, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin, Germany.
  • Saliba AE; Helmholtz Institute for RNA-based Infection Research (HIRI), Helmholtz Center for Infection Research (HZI), Würzburg, Germany.
  • Eils R; Center for Digital Health, Berlin Institute of Health (BIH), Charité - Universitätsmedizin Berlin, Berlin, Germany; German Center for Lung Research (DZL), Berlin, Germany.
  • Lehmann I; Center for Digital Health, Berlin Institute of Health (BIH), Charité - Universitätsmedizin Berlin, Berlin, Germany; German Center for Lung Research (DZL), Berlin, Germany.
  • Mall MA; Department of Pediatric Respiratory Medicine, Immunology and Critical Care Medicine, Charité - Universitätsmedizin Berlin, Berlin, Germany; German Center for Lung Research (DZL), Associated Partner, Berlin, Germany; Berlin Institute of Health (BIH), Charité - Universitätsmedizin Berlin, Berlin, Germ
  • Stricker S; Department of Pediatric Respiratory Medicine, Immunology and Critical Care Medicine, Charité - Universitätsmedizin Berlin, Berlin, Germany.
  • Röhmel J; Department of Pediatric Respiratory Medicine, Immunology and Critical Care Medicine, Charité - Universitätsmedizin Berlin, Berlin, Germany.
  • Corman VM; Institute of Virology, Charité - Universitätsmedizin Berlin, Berlin, Germany.
  • Beule D; Core Unit Bioinformatics, Berlin Institute of Health (BIH), Charité - Universitätsmedizin Berlin, Berlin, Germany.
  • Wyler E; Max-Delbrück-Center for Molecular Medicine in the Helmholtz Association, Berlin Institute for Medical Systems Biology, Berlin, Germany.
  • Landthaler M; IRI Life Sciences, Humboldt-Universität zu Berlin, Berlin, Germany; Max-Delbrück-Center for Molecular Medicine in the Helmholtz Association, Berlin Institute for Medical Systems Biology, Berlin, Germany.
  • Obermayer B; Core Unit Bioinformatics, Berlin Institute of Health (BIH), Charité - Universitätsmedizin Berlin, Berlin, Germany.
  • von Stillfried S; Institute of Pathology, University Clinic Aachen, RWTH Aachen, Aachen, Germany.
  • Boor P; Institute of Pathology, University Clinic Aachen, RWTH Aachen, Aachen, Germany; Department of Nephrology, University Clinic Aachen, RWTH Aachen, Aachen, Germany; Electron Microscopy Facility, University Clinic Aachen, RWTH Aachen, Aachen, Germany.
  • Demir M; Department of Hepatology and Gastroenterology, Charité - Universitätsmedizin Berlin, Berlin, Germany.
  • Wesselmann H; Department of Infectious Diseases and Respiratory Medicine, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin, Germany.
  • Suttorp N; Department of Infectious Diseases and Respiratory Medicine, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin, Germany; German Center for Lung Research (DZL), Gießen, Germany.
  • Uhrig A; Department of Infectious Diseases and Respiratory Medicine, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin, Germany.
  • Müller-Redetzky H; Department of Infectious Diseases and Respiratory Medicine, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin, Germany.
  • Nattermann J; Department of Internal Medicine I, University Hospital Bonn, Bonn, Germany.
  • Kuebler WM; Institute of Physiology, Charité - Universitätsmedizin Berlin, Berlin, Germany.
  • Meisel C; Institute of Medical Immunology, Charité - Universitätsmedizin Berlin, Berlin, Germany; Department of Immunology, Labor Berlin, Charité Vivantes, Berlin, Germany.
Cell ; 185(3): 493-512.e25, 2022 02 03.
Article en En | MEDLINE | ID: mdl-35032429
ABSTRACT
Severe COVID-19 is linked to both dysfunctional immune response and unrestrained immunopathology, and it remains unclear whether T cells contribute to disease pathology. Here, we combined single-cell transcriptomics and single-cell proteomics with mechanistic studies to assess pathogenic T cell functions and inducing signals. We identified highly activated CD16+ T cells with increased cytotoxic functions in severe COVID-19. CD16 expression enabled immune-complex-mediated, T cell receptor-independent degranulation and cytotoxicity not found in other diseases. CD16+ T cells from COVID-19 patients promoted microvascular endothelial cell injury and release of neutrophil and monocyte chemoattractants. CD16+ T cell clones persisted beyond acute disease maintaining their cytotoxic phenotype. Increased generation of C3a in severe COVID-19 induced activated CD16+ cytotoxic T cells. Proportions of activated CD16+ T cells and plasma levels of complement proteins upstream of C3a were associated with fatal outcome of COVID-19, supporting a pathological role of exacerbated cytotoxicity and complement activation in COVID-19.
Asunto(s)
Palabras clave

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Linfocitos T Citotóxicos / Activación de Complemento / Proteoma / Transcriptoma / SARS-CoV-2 / COVID-19 Tipo de estudio: Prognostic_studies Límite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Cell Año: 2022 Tipo del documento: Article País de afiliación: Alemania

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Linfocitos T Citotóxicos / Activación de Complemento / Proteoma / Transcriptoma / SARS-CoV-2 / COVID-19 Tipo de estudio: Prognostic_studies Límite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Cell Año: 2022 Tipo del documento: Article País de afiliación: Alemania